Adamis Pharmaceuticals Corp. (ADMP) Short Interest Up 31.2% in September
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 1,833,763 shares, a growth of 31.2% from the August 31st total of 1,397,862 shares. Based on an average trading volume of 630,643 shares, the short-interest ratio is presently 2.9 days. Approximately 10.5% of the shares of the company are short sold.
Separately, Maxim Group reduced their target price on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 21st.
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) opened at 3.32 on Wednesday. The company’s market capitalization is $69.34 million. The stock’s 50 day moving average is $3.03 and its 200-day moving average is $4.83. Adamis Pharmaceuticals Corp. has a 52-week low of $2.50 and a 52-week high of $10.98.
Large investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in Adamis Pharmaceuticals Corp. by 24.7% in the second quarter. BlackRock Fund Advisors now owns 49,806 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 9,868 shares during the last quarter. Walleye Trading LLC raised its stake in Adamis Pharmaceuticals Corp. by 118.1% in the second quarter. Walleye Trading LLC now owns 275,078 shares of the specialty pharmaceutical company’s stock valued at $770,000 after buying an additional 148,966 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Adamis Pharmaceuticals Corp. by 21.8% in the second quarter. Vanguard Group Inc. now owns 335,814 shares of the specialty pharmaceutical company’s stock valued at $940,000 after buying an additional 60,197 shares during the last quarter. 9.70% of the stock is currently owned by institutional investors and hedge funds.
Adamis Pharmaceuticals Corp. Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Stock Ratings for Adamis Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.